Eli Lilly and Company (NYSE:LLY) Price Target Raised to $1,033.00 at Truist Financial

by · The Markets Daily

Eli Lilly and Company (NYSE:LLY – Free Report) had its target price raised by Truist Financial from $1,000.00 to $1,033.00 in a report published on Thursday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

LLY has been the subject of a number of other research reports. Morgan Stanley restated an overweight rating and issued a $1,106.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Evercore ISI raised shares of Eli Lilly and Company to a hold rating in a research note on Thursday, September 5th. Deutsche Bank Aktiengesellschaft reaffirmed a buy rating and set a $1,025.00 target price on shares of Eli Lilly and Company in a report on Thursday, October 3rd. Cantor Fitzgerald reissued an overweight rating and issued a $885.00 price target on shares of Eli Lilly and Company in a research note on Monday, September 16th. Finally, Guggenheim upped their price target on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a buy rating in a research report on Friday, August 16th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus target price of $979.29.

Read Our Latest Stock Report on Eli Lilly and Company

Eli Lilly and Company Price Performance

Shares of LLY traded up $2.97 during mid-day trading on Thursday, reaching $913.66. 247,852 shares of the stock traded hands, compared to its average volume of 2,998,796. The company has a market cap of $868.37 billion, a price-to-earnings ratio of 112.15, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a 1 year low of $547.61 and a 1 year high of $972.53. The firm has a fifty day moving average price of $908.28 and a 200 day moving average price of $851.21. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The firm had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. As a group, equities research analysts predict that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Hedge Funds Weigh In On Eli Lilly and Company

Several hedge funds and other institutional investors have recently modified their holdings of the company. Twelve Points Wealth Management LLC increased its stake in Eli Lilly and Company by 1.4% during the 2nd quarter. Twelve Points Wealth Management LLC now owns 811 shares of the company’s stock worth $734,000 after buying an additional 11 shares in the last quarter. Verum Partners LLC raised its position in Eli Lilly and Company by 1.5% in the second quarter. Verum Partners LLC now owns 731 shares of the company’s stock valued at $662,000 after purchasing an additional 11 shares during the period. Beaird Harris Wealth Management LLC lifted its position in Eli Lilly and Company by 2.2% in the second quarter. Beaird Harris Wealth Management LLC now owns 512 shares of the company’s stock valued at $464,000 after buying an additional 11 shares during the last quarter. Acorn Creek Capital LLC lifted its holdings in shares of Eli Lilly and Company by 1.3% in the 2nd quarter. Acorn Creek Capital LLC now owns 927 shares of the company’s stock worth $840,000 after acquiring an additional 12 shares during the last quarter. Finally, Thompson Davis & CO. Inc. boosted its position in shares of Eli Lilly and Company by 0.7% during the second quarter. Thompson Davis & CO. Inc. now owns 1,687 shares of the company’s stock worth $1,527,000 after buying an additional 12 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Company Profile

(Get Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Further Reading